<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01420523</url>
  </required_header>
  <id_info>
    <org_study_id>2011-002483-24</org_study_id>
    <nct_id>NCT01420523</nct_id>
  </id_info>
  <brief_title>Evaluation of Raltegravir Plus Maraviroc Therapy in Controlled HIV Patients Presenting With Lipohypertrophy</brief_title>
  <acronym>ROCnRAL</acronym>
  <official_title>Phase II Pilot Study Evaluating the Efficacy of Dual Therapy With Raltegravir Plus Maraviroc in Patients Receiving Suppressive Antiretroviral Therapy and Presenting With Lipohypertrophy (ANRS 157 ROCnRAL).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ANRS, Emerging Infectious Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ANRS, Emerging Infectious Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of antiretroviral therapy combining Raltegravir and Maraviroc in patients with&#xD;
      virological success, presenting with clinical lipohypertrophy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the ability to maintain the plasma HIV viral load below the threshold needed for&#xD;
      detection (&lt; 50 copies/mL) at 24 weeks of raltegravir/maraviroc therapy without NRTIs and&#xD;
      PIs, in patients with virological success and presenting with clinical lipohypertrophy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Virological failure</measure>
    <time_frame>Week 24</time_frame>
    <description>Occurrence of virological failure, as verified by 2 consecutive plasma viral load measurements &gt; 50 copies/mL, taken 2 to 4 weeks apart at most, during the first 24 weeks.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viro-immunological efficacy</measure>
    <time_frame>Between baseline and W48</time_frame>
    <description>Proportion of patients with a HIV RNA viral load &lt; 50 copies/mL.&#xD;
Proportion of patients discontinuing the therapy:&#xD;
Plasma genotypic resistance profile where the viral load is &gt; 50 copies/mL.&#xD;
Evaluation of DNA/RNA tropism in the event of failure.&#xD;
Evaluation of plasma HIV RNA where the viral load is &lt; 50 copies/mL, through ultrasensitive PCR testing.&#xD;
Evolution of the CD4 and CD8 T-cell counts.&#xD;
Blood concentration of raltegravir and maraviroc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerability criteria and metabolic impact</measure>
    <time_frame>Between baseline and W48</time_frame>
    <description>Changes in glucose and lipid balance.&#xD;
Changes in anthropometric measurements.&#xD;
Number and severity of clinical and biological adverse effects.&#xD;
Changes in bone mineral density and body composition, as measured by DEXA scan.&#xD;
Changes in inflammation and endothelial activation markers between baseline and W48&#xD;
Measurement of fat cells differentiation markers in adipose tissue biopsy samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Between baseline and W48</time_frame>
    <description>• Assessment of compliance conducted at screening and at W24 and 48.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Between baseline and W48</time_frame>
    <description>• Assessment of health-related quality of life conducted at baseline and at W24 and 48.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <condition>Lipohypertrophy</condition>
  <arm_group>
    <arm_group_label>Raltegravir-Maraviroc</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir-Maraviroc</intervention_name>
    <description>Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day</description>
    <arm_group_label>Raltegravir-Maraviroc</arm_group_label>
    <other_name>Isentress and Celsentri</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients infected with HIV-1 type B or CRF02.&#xD;
&#xD;
          -  ≥ 18 years old&#xD;
&#xD;
          -  Patients who have been receiving antiretroviral therapy for at least 5 years, and&#xD;
             whose treatment has been stable for at least 6 months.&#xD;
&#xD;
          -  Patients whose plasma viral load has been undetectable (below 200 copies/mL) over the&#xD;
             last 24 months, and &lt; 50 copies/mL for at least 12 months.&#xD;
&#xD;
          -  Patients with an R5* tropic virus, as determined through DNA and with CD4 nadir ≥&#xD;
             100/mm3&#xD;
&#xD;
          -  Patients presenting with clinical lipohypertrophy recognized by themselves and by&#xD;
             their doctors, and defined by increased volume of the abdominal and/or thoracic and/or&#xD;
             cervical area (buffalo hump).&#xD;
&#xD;
          -  Patients who have never been treated with raltegravir.&#xD;
&#xD;
          -  Patients who have never been treated with maraviroc.&#xD;
&#xD;
          -  Efficient contraception for women&#xD;
&#xD;
          -  Free and informed written consent, signed by the patient and the investigator.&#xD;
&#xD;
          -  Patients with health insurance. * To increase the certainty of selecting patients with&#xD;
             an R5 virus, the HIV-1 tropism will be determined by the genotype method and&#xD;
             interpreted with the Geno2pheno[coreceptor] algorithm and a false positive rate&#xD;
             threshold for X4 virus at 20%, rather than the usual 10%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  X4, X4/5 or undetermined tropism of the HIV virus.&#xD;
&#xD;
          -  HIV-2 or coinfection HIV-1/HIV-2.&#xD;
&#xD;
          -  Chronic viral hepatitis B.&#xD;
&#xD;
          -  Chronic viral hepatitis C requiring specific treatment over the first 24 weeks.&#xD;
&#xD;
          -  Treatment with growth hormones.&#xD;
&#xD;
          -  Hypolipemic or diabetes treatment, begun within the last 3 months.&#xD;
&#xD;
          -  Pregnant or breastfeeding women.&#xD;
&#xD;
          -  Haemoglobin &lt; 7g/dl, neutrophils &lt; 500/mm3, platelets &lt; 50 000/mm3, creatinine&#xD;
             clearance &lt; 50 mL/min, alkaline phosphatases, ASAT, ALAT or bilirubin ≥ 3 times the&#xD;
             upper limit of the normal range (N).&#xD;
&#xD;
          -  Antiretroviral treatment associated to enzymatic inducer.&#xD;
&#xD;
          -  Chronic alcohol consumption.&#xD;
&#xD;
          -  Subjects under &quot;sauvegarde de justice&quot; (judicial protection due to temporarily and&#xD;
             slightly diminished mental or physical faculties), or under legal guardianship.&#xD;
&#xD;
          -  Subjects participating in another clinical trial evaluating different therapies and&#xD;
             including an exclusion period that is still in force during the screening phase.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine Katlama, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Groupe hospitalier Pitié-Salpétrière</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dominique Costagliola</last_name>
    <role>Study Director</role>
    <affiliation>Inserm U943</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Pitié Salpétrière</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.anrs.fr</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2015</verification_date>
  <study_first_submitted>August 18, 2011</study_first_submitted>
  <study_first_submitted_qc>August 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2011</study_first_posted>
  <last_update_submitted>July 23, 2015</last_update_submitted>
  <last_update_submitted_qc>July 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Lipohypertrophy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

